Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients

@article{Silvani2004PhaseIT,
  title={Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients},
  author={Antonio Silvani and Marica Eoli and Andrea Salmaggi and Elena A. Lamperti and Elio Maccagnano and Giovanni Broggi and Amerigo Boiardi},
  journal={Journal of Neuro-Oncology},
  year={2004},
  volume={66},
  pages={203-208}
}
We report a phase II trial of cisplatinum and temozolomide (TMZ) combination in recurrent malignant glioma patients. The DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGAT) is important in glioblastoma resistance to alkylating antitumor agents. In vitro, cisplatin (CDDP) decreases MGMT activity in a time- and dose-dependent manner. Thirty-three recurrent malignant glioma patients (20 GBM-13 AA) were treated at recurrence or progression with a CDDP and TMZ association. On days 1 and… CONTINUE READING